Literature DB >> 9548607

Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion.

J F Thompson1, P C Kam, R C Waugh, C R Harman.   

Abstract

Isolated limb perfusion (ILP) with cytotoxic agents is an effective but complex procedure. Isolated limb infusion (ILI) has been developed as a simpler alternative. Catheters are inserted percutaneously into the axial artery and vein of the affected limb and a pneumatic tourniquet is inflated proximally. Cytotoxic agents are then infused through the arterial catheter and circulated with a syringe for 15 to 20 minutes. Progressive hypoxia occurs, but normothermia is maintained. To date, 175 ILIs have been performed: 164 for melanoma and 11 for other tumours. Results obtained are similar to those obtained by conventional ILP. Morbidity is low and treatment of frail and elderly patients who would not tolerate ILP is possible. An elective double ILI protocol can be used to obtain the additional benefits of fractionated chemotherapy. The possibility of increasing ILI response rates by using other drugs and drug combinations and by multiple fractionated dosing is being investigated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548607     DOI: 10.1002/(sici)1098-2388(199804/05)14:3<238::aid-ssu8>3.0.co;2-9

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  39 in total

Review 1.  Regional therapies for locoregionally advanced and unresectable melanoma.

Authors:  Evan S Weitman; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-05-08       Impact factor: 5.150

Review 2.  Current treatment of locoregional recurrence of melanoma.

Authors:  Malcolm Hart Squires; Keith A Delman
Journal:  Curr Oncol Rep       Date:  2013-10       Impact factor: 5.075

Review 3.  A surgical perspective report on melanoma management.

Authors:  Brian D Wernick; Neha Goel; Francis Sw Zih; Jeffrey M Farma
Journal:  Melanoma Manag       Date:  2017-05-15

Review 4.  Subcutaneous metastases from melanoma: a discussion of clinical experience.

Authors:  Piotr Rutkowski; Marcin Zdzienicki; Katarzyna Kozak
Journal:  Melanoma Manag       Date:  2014-09-05

5.  Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion.

Authors:  Jerry R Mendell; Louis G Chicoine; Samiah A Al-Zaidy; Zarife Sahenk; Kelly Lehman; Linda Lowes; Natalie Miller; Lindsay Alfano; Beverly Galliers; Sarah Lewis; Darren Murrey; Ellyn Peterson; Danielle A Griffin; Kathleen Church; Sharon Cheatham; John Cheatham; Mark J Hogan; Louise R Rodino-Klapac
Journal:  Hum Gene Ther       Date:  2019-04-19       Impact factor: 5.695

Review 6.  Regional therapies for in-transit disease.

Authors:  Paul J Speicher; Claire H Meriwether; Douglas S Tyler
Journal:  Surg Oncol Clin N Am       Date:  2015-01-30       Impact factor: 3.495

7.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Isolated limb infusion in a series of over 100 infusions: a single-center experience.

Authors:  Joyce Wong; Y Ann Chen; Kate J Fisher; Jonathan S Zager
Journal:  Ann Surg Oncol       Date:  2013-03-02       Impact factor: 5.344

9.  Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?

Authors:  N McMahon; T Y Cheng; G M Beasley; I Spasojevic; W Petros; C K Augustine; P Zipfel; J C Padussis; G Sanders; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2009-01-30       Impact factor: 5.344

Review 10.  Surgery and radiotherapy in the treatment of cutaneous melanoma.

Authors:  A Testori; P Rutkowski; J Marsden; L Bastholt; V Chiarion-Sileni; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.